Apr 13, 2012, 2:44 PM EDT
Don’t expect to see Daniel Sedin in the Vancouver lineup tonight when the Canucks and Kings meet for Game 2 at Rogers Arena.
According to The Province, Sedin (concussion) skated by himself this morning, about 90 minutes before the rest of the team practiced.
Coach Alain Vigneault wouldn’t (or couldn’t) say if his top scorer will make the trip to Los Angeles for Sunday’s Game 3.
The Canucks are expected to make two line-up changes for Game 2.
First, Andrew Ebbett will replace the suspended Byron Bitz as the fourth-line center.
Ballard hasn’t played since Feb. 7 due to a concussion, but says he’s “all cleared and ready to go.”
Vigneault hasn’t confirmed Ballard is in, but according to TSN’s Farhan Lalji, “it seems quite obvious he is.”
So what kind of Canucks team can we expect to see tonight?
“I think our main concern tonight is going to be stay out of the [penalty] box and keep the game flowing,” said Ryan Kesler.
- Here’s your Stanley Cup playoff TV schedule for tonight 2
- (Report) Pens’ Rutherford to columnist: ‘You’re a (expletive) jerk’ 24
- Ducks silence Winnipeg’s whiteout crowd with OT win, push Jets to brink of elimination 26
- Video: Wild chase the Blues away to take series lead 42
- Too little, too late: Rangers stifle Penguins for 2-1 series lead 96
- Video: Jets fans celebrate return of playoff hockey with whiteout in Winnipeg 5
- Would McLellan like to coach McDavid? ‘You can have the best player and still not have the best team’ 23
- Burrows’ instigator suspension rescinded, allowed to play Game 4 24
- No hearing scheduled for Hamhuis after Bennett headshot 13
- Sharks and McLellan have ‘mutually agreed’ to part ways 50
- Of course they did: Oilers win 2015 NHL Draft Lottery, will select first overall (172)
- Stone suffered microfracture on Subban slash, Sens confirm (102)
- Report: Kings’ Stoll arrested for cocaine, MDMA possession (Updated) (99)
- Too little, too late: Rangers stifle Penguins for 2-1 series lead (96)
- Eichel understands Murray’s disappointment, but ‘extreme competitor’ has ‘a lot to offer’ (95)